Respiratory syncytial virus(RSV)is a major global health threat,causing severe respiratory disease in infants,the elderly,and immunocompromised individuals—often surpassing the impact of influenza.Yet,effective RSV t...Respiratory syncytial virus(RSV)is a major global health threat,causing severe respiratory disease in infants,the elderly,and immunocompromised individuals—often surpassing the impact of influenza.Yet,effective RSV therapies remain limited.We describe anti-RSV ssDNA aptamers,selected via Systematic Evolution of Ligands by Exponential Enrichment(SELEX),that bind the RSV glycoprotein(G)with nanomolar affinity.These aptamer-based therapeutics demonstrated potent antiviral activity against RSV.We further established that the binding domains of these aptamers are critical for their antiviral function.Our findings highlight highly active aptamers as a promising strategy to combat RSV infections.展开更多
基金supported by the National Natural Science Foundation of China(82394465,82394464)The CAMS Innovation Fund for Medical Sciences(CIFMS)(2025-I2M-XHXX-105,2024-I2M-ZH-012-2402-01,2021-I2M-1-048,2021-I2M-1-039,China).
文摘Respiratory syncytial virus(RSV)is a major global health threat,causing severe respiratory disease in infants,the elderly,and immunocompromised individuals—often surpassing the impact of influenza.Yet,effective RSV therapies remain limited.We describe anti-RSV ssDNA aptamers,selected via Systematic Evolution of Ligands by Exponential Enrichment(SELEX),that bind the RSV glycoprotein(G)with nanomolar affinity.These aptamer-based therapeutics demonstrated potent antiviral activity against RSV.We further established that the binding domains of these aptamers are critical for their antiviral function.Our findings highlight highly active aptamers as a promising strategy to combat RSV infections.
